In consultation: Guidance and quality standards
Showing 1 to 4 of 4
Title | Consultation | Type | Consultation end date |
---|---|---|---|
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651] | Draft guidance | Technology appraisal guidance | |
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130] | Evaluation consultation | Highly specialised technology | |
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Draft guidance | Technology appraisal guidance | |
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Draft guidance | Technology appraisal guidance |